These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
181 related items for PubMed ID: 11138691
1. Marrow-sparing effects of 117mSn(4+)diethylenetriaminepentaacetic acid for radionuclide therapy of bone cancer. Bishayee A, Rao DV, Srivastava SC, Bouchet LG, Bolch WE, Howell RW. J Nucl Med; 2000 Dec; 41(12):2043-50. PubMed ID: 11138691 [Abstract] [Full Text] [Related]
2. Marrow toxicity of 33P-versus 32P-orthophosphate: implications for therapy of bone pain and bone metastases. Goddu SM, Bishayee A, Bouchet LG, Bolch WE, Rao DV, Howell RW. J Nucl Med; 2000 May; 41(5):941-51. PubMed ID: 10809212 [Abstract] [Full Text] [Related]
3. Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions. Bouchet LG, Bolch WE, Goddu SM, Howell RW, Rao DV. J Nucl Med; 2000 Apr; 41(4):682-7. PubMed ID: 10768569 [Abstract] [Full Text] [Related]
4. Biologic dosimetry of bone marrow: induction of micronuclei in reticulocytes after exposure to 32P and 90Y. Lenarczyk M, Goddu SM, Rao DV, Howell RW. J Nucl Med; 2001 Jan; 42(1):162-9. PubMed ID: 11197968 [Abstract] [Full Text] [Related]
5. Biological dosimetry of bone marrow for incorporated yttrium-90. Goddu SM, Howell RW, Giuliani DC, Rao DV. J Nucl Med; 1998 Mar; 39(3):547-52. PubMed ID: 9529309 [Abstract] [Full Text] [Related]
6. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters. Behr TM, Sgouros G, Stabin MG, Béhé M, Angerstein C, Blumenthal RD, Apostolidis C, Molinet R, Sharkey RM, Koch L, Goldenberg DM, Becker W. Clin Cancer Res; 1999 Oct; 5(10 Suppl):3031s-3043s. PubMed ID: 10541340 [Abstract] [Full Text] [Related]
7. Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice. Elgqvist J, Bernhardt P, Hultborn R, Jensen H, Karlsson B, Lindegren S, Warnhammar E, Jacobsson L. J Nucl Med; 2005 Mar; 46(3):464-71. PubMed ID: 15750160 [Abstract] [Full Text] [Related]
8. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients. Siegel JA, Yeldell D, Goldenberg DM, Stabin MG, Sparks RB, Sharkey RM, Brenner A, Blumenthal RD. J Nucl Med; 2003 Jan; 44(1):67-76. PubMed ID: 12515878 [Abstract] [Full Text] [Related]
9. Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity. Elgqvist J, Andersson H, Bäck T, Claesson I, Hultborn R, Jensen H, Lindegren S, Olsson M, Palm S, Warnhammar E, Jacobsson L. Nucl Med Biol; 2006 Nov; 33(8):1065-72. PubMed ID: 17127181 [Abstract] [Full Text] [Related]
10. Treatment of metastatic bone pain with tin-117m Stannic diethylenetriaminepentaacetic acid: a phase I/II clinical study. Srivastava SC, Atkins HL, Krishnamurthy GT, Zanzi I, Silberstein EB, Meinken G, Mausner LF, Swailem F, D'Alessandro T, Cabahug CJ, Lau Y, Park T, Madajewicz S. Clin Cancer Res; 1998 Jan; 4(1):61-8. PubMed ID: 9516953 [Abstract] [Full Text] [Related]
11. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts. de Klerk JM, van Dieren EB, van het Schip AD, Hoekstra A, Zonnenberg BA, van Dijk A, Rutgers DH, Blijham GH, van Rijk PP. J Nucl Med; 1996 Jan; 37(1):38-41. PubMed ID: 8543998 [Abstract] [Full Text] [Related]
12. S values for radionuclides localized within the skeleton. Bouchet LG, Bolch WE, Howell RW, Rao DV. J Nucl Med; 2000 Jan; 41(1):189-212. PubMed ID: 10647623 [Abstract] [Full Text] [Related]
13. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Henriksen G, Breistøl K, Bruland ØS, Fodstad Ø, Larsen RH. Cancer Res; 2002 Jun 01; 62(11):3120-5. PubMed ID: 12036923 [Abstract] [Full Text] [Related]
14. Peptide receptor radionuclide therapy in vitro using [111In-DTPA0]octreotide. Capello A, Krenning EP, Breeman WA, Bernard BF, de Jong M. J Nucl Med; 2003 Jan 01; 44(1):98-104. PubMed ID: 12515882 [Abstract] [Full Text] [Related]
15. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts. Chen P, Cameron R, Wang J, Vallis KA, Reilly RM. J Nucl Med; 2003 Sep 01; 44(9):1469-78. PubMed ID: 12960194 [Abstract] [Full Text] [Related]